We found that initiator caspase-9 was processed at very low levels after resveratrol treatment (Figure 3F) whereas caspase 3 was not immunodetected in MCF-7 breast cancer cells in agreement with previous studies. This evidence concerns the gene CASP9 and breast cancer.